Delivery Order SPE2DR25D9331-SPE2DR26FQQD9
- Not listed
- The Defense Logistics Agency awarded a $46,509.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency awarded a $41,858.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award...
- The Defense Logistics Agency issued a delivery order valued at $4,905.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 2, 2026, with an ultimate completion date of January 26, 2026, operates under a firm fixed-price contract structure with no set-aside designation. This award falls under DMS Pharmaceutical Group's Pharmaceutical Prime...
- The Defense Logistics Agency awarded a $29,434.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 30, 2026, with an ultimate completion date of February 23, 2026, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS...
- The Defense Logistics Agency (DLA) awarded a $139,529.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta (420 mg/14 mL vials). The delivery order, issued on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $49,058.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on January 22, 2026, with an ultimate completion date of February 12, 2026, was issued without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal...
- The Defense Logistics Agency awarded a delivery order valued at $4,905.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order, issued on January 16, 2026, with an ultimate completion date of February 9, 2026, operates under a firm fixed-price arrangement with no set-aside designation. This award is issued under DMS Pharmaceutical Group's Indefinite Delivery...
- The Defense Logistics Agency awarded a $58,869.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on January 12, 2026, with an ultimate completion date of February 3, 2026, and carries no set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical Group's Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $27,905.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on November 18, 2025, with an ultimate completion date of December 10, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement....
- The Defense Logistics Agency issued a delivery order valued at approximately $29.4K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, awarded on January 22, 2026, represents performance through February 12, 2026, and carries no set-aside designation, indicating the awardee competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- SPE2DR25D9331Indefinite Delivery Contract
- SPE2DR25D9331-SPE2DR26FQQD9Delivery Order
The Defense Logistics Agency (DLA) awarded a $29,434.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, a specialty pharmaceutical used in oncology treatment. The delivery order, issued on February 3, 2026, with an ultimate completion date of February 25, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy that positions multiple regional prime vendor contractors as critical suppliers of pharmaceutical products to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group demonstrates substantial capability as a federal pharmaceutical supplier through its extensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's established performance across numerous delivery orders—ranging from small purchases under $100 to awards exceeding $115,000—and its registration in the System for Award Management since July 18, 2001, underscore its reliability within the federal military medical supply chain. The PPV-G GEN V contract structure provides a 30-month base period with three optional 30-month renewal periods extending through December 31, 2036, enabling the DLA to issue firm fixed-price delivery orders for recurring pharmaceutical supply needs supporting military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.4k | 2/2/26 |